^
Association details:
| Biomarker: | ER overexpression |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of ERa-36 expression with the de novo resistance of tamoxifen in ER-positive breast cancer
Published date:
05/28/2021
Excerpt:
A total of 50 locally advanced breast cancer cases were included in this study, 22 cases (44%) had overexpression of ERα-36, and 28 cases (56%) had not...expression of ER-α36 with de novo resistance of tamoxifen in ER-positive breast cancer. ER-α36 could act as a worth considering biomarker for de novo resistance of tamoxifen in therapeutic strategies.
DOI:
10.3233/BD-219019
